170 related articles for article (PubMed ID: 22362419)
1. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.
Abourbeh G; Shir A; Mishani E; Ogris M; Rödl W; Wagner E; Levitzki A
IUBMB Life; 2012 Apr; 64(4):324-30. PubMed ID: 22362419
[TBL] [Abstract][Full Text] [Related]
2. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.
Shir A; Ogris M; Roedl W; Wagner E; Levitzki A
Clin Cancer Res; 2011 Mar; 17(5):1033-43. PubMed ID: 21196415
[TBL] [Abstract][Full Text] [Related]
3. Peptide GE11-Polyethylene Glycol-Polyethylenimine for targeted gene delivery in laryngeal cancer.
Ren H; Zhou L; Liu M; Lu W; Gao C
Med Oncol; 2015 Jul; 32(7):185. PubMed ID: 26008151
[TBL] [Abstract][Full Text] [Related]
4. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.
Schäfer A; Pahnke A; Schaffert D; van Weerden WM; de Ridder CM; Rödl W; Vetter A; Spitzweg C; Kraaij R; Wagner E; Ogris M
Hum Gene Ther; 2011 Dec; 22(12):1463-73. PubMed ID: 21644815
[TBL] [Abstract][Full Text] [Related]
5. Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier.
Schaffert D; Kiss M; Rödl W; Shir A; Levitzki A; Ogris M; Wagner E
Pharm Res; 2011 Apr; 28(4):731-41. PubMed ID: 20694527
[TBL] [Abstract][Full Text] [Related]
6. Structure-based peptide ligand design for improved epidermal growth factor receptor targeted gene delivery.
Decker S; Taschauer A; Geppl E; Pirhofer V; Schauer M; Pöschl S; Kopp F; Richter L; Ecker GF; Sami H; Ogris M
Eur J Pharm Biopharm; 2022 Jul; 176():211-221. PubMed ID: 35584718
[TBL] [Abstract][Full Text] [Related]
7. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment.
Hailing T; Yonghong P; Yufeng Z; Haitao T
J Control Release; 2022 Sep; 349():592-605. PubMed ID: 35872181
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
Go G; Park HJ; Lee JH; Yun CW; Lee SH
Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
[TBL] [Abstract][Full Text] [Related]
9. Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF.
Edinger N; Lebendiker M; Klein S; Zigler M; Langut Y; Levitzki A
PLoS One; 2016; 11(9):e0162321. PubMed ID: 27598772
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.
Li Z; Zhao R; Wu X; Sun Y; Yao M; Li J; Xu Y; Gu J
FASEB J; 2005 Dec; 19(14):1978-85. PubMed ID: 16319141
[TBL] [Abstract][Full Text] [Related]
11.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
12. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Willhauck MJ; Dohmen C; Wunderlich N; Knoop K; Zach C; Senekowitsch-Schmidtke R; Gildehaus FJ; Ziegler S; Fürst S; Göke B; Wagner E; Ogris M; Spitzweg C
Hum Gene Ther; 2011 Dec; 22(12):1563-74. PubMed ID: 21851208
[TBL] [Abstract][Full Text] [Related]
13. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
[TBL] [Abstract][Full Text] [Related]
14. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.
Klutz K; Schaffert D; Willhauck MJ; Grünwald GK; Haase R; Wunderlich N; Zach C; Gildehaus FJ; Senekowitsch-Schmidtke R; Göke B; Wagner E; Ogris M; Spitzweg C
Mol Ther; 2011 Apr; 19(4):676-85. PubMed ID: 21245850
[TBL] [Abstract][Full Text] [Related]
16. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of [
Li X; Hu K; Liu W; Wei Y; Sha R; Long Y; Han Y; Sun P; Wu H; Li G; Tang G; Huang S
Nucl Med Biol; 2020; 90-91():84-92. PubMed ID: 33189948
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligands.
Lee D; Lee YM; Kim J; Lee MK; Kim WJ
Biomater Sci; 2015 Jul; 3(7):1096-104. PubMed ID: 26221943
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of ligand-EGFR interactions: a platform for screening targeting molecules.
Kuo WT; Lin WC; Chang KC; Huang JY; Yen KC; Young IC; Sun YJ; Lin FH
PLoS One; 2015; 10(2):e0116610. PubMed ID: 25723471
[TBL] [Abstract][Full Text] [Related]
20. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
